If you want to know more about a drug, Health Canada provides information online through several websites. However, some information appears to be getting harder to find.
Academic rigor, journalistic flair
Articles on Health Canada
Displaying 1 - 20 of 23 articles
Canada is long-overdue for scientifically-driven, robust and transparent pesticide regulation. A newly created Science Advisory Committee aims to address this.
The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.
Health Canada continues to monitor newly approved drugs to determine if the benefits identified in the pre-market trials hold up to further scrutiny. Canadians need better access to that information.
The pharma industry claims lower prescription drug prices will mean less access to new medication for Canadians. It’s an old threat that pits profits against patients’ rights to affordable drugs.
Generic drug names are often long, but they can tell doctors what type of medicine it is and how it works. But it’s brand names that appear first and most prominently in Health Canada materials.
When drugs are taken off the market because they are either unsafe or don’t work, do pharma companies admit that there are problems? Or do they deny the evidence?
When making the decision whether to vaccinate children aged five to 11 against COVID-19, regulators in Canada must rely on sound ethics as well as sound science.
Decriminalization is an important step in addressing the overdose crisis, but it is crucial that other approaches — like regulation — are also in place.
Health Canada devotes far more resources to getting new drugs onto the market compared to making sure that drugs already being sold are safe.
Will a vaccine for COVID-19 be safe? Animal testing, human clinical trials and post-approval surveillance give us good grounds to believe that a future approved vaccine will work and be safe.
Seven million French-speaking Canadians shouldn’t have to decipher English-only labels during the pandemic. Ottawa must take into account the fundamental rights and safety of all Canadians.
As cannabis candies and chocolates become widely available, sweeter edibles may be more appealing to youth. We need to work to minimize the potential health impacts.
Drug companies have a job to do and so does Health Canada. When the relationship becomes murky, the public are at risk.
Health Canada must be unbiased and it must be seen to be unbiased – so that Canadians get the best possible value out of prescription drugs.
Federal officials have repeatedly claimed cannabis supplies are sufficient. But their own data suggest otherwise.
It’s time Health Canada took back the regulation of drug advertising – to protect consumers.
Prescription drugs are policed by industry and Health Canada has never prosecuted a drug company for illegally marketing a drug.
The cost of a life-saving drug in Canada is rising by 3,000 per cent. A national pharmacare plan could bring order to this chaotic world of Canadian drug prices.
Health Canada is proposing to allow some prescription drugs into the country with only ‘cursory clinical review.’ Here’s why we should be worried.
Top contributors
-
Joel Lexchin is a Friend of The Conversation.Professor Emeritus of Health Policy and Management, York University, Canada
-
Assistant Professor and Canada Research Chair for Radiation Exposure Disease, University of Calgary
-
Assistant Professor and Canada Research Chair in the Politics of Reproduction, University of Waterloo
-
Professor, School of Occupational and Public Health, Toronto Metropolitan University
-
Professor/Professeure titulaire, Eau Terre Environnement Research Centre, Institut national de la recherche scientifique (INRS)
-
Director of the Health Law Institute at the Schulich School of Law, Dalhousie University
-
Associate Professor of Philosophy and Core Member of the Rotman Institute of Philosophy, Western University
-
Associate Professor, Department of Family and Community Medicine, University of Toronto
-
Associate Professor, Operations Research, Brock University
-
Assistant Professor, Department of Family and Community Medicine, University of Toronto
-
Assistant Professor in the School of Criminology, Simon Fraser University
-
Associate Professor and Entomologist, University of Saskatchewan
-
Professor of Health Economics, Queen's University Belfast
-
Associate professor, School of Public Health, University of Alberta
-
Professor, School of Population and Public Health, University of British Columbia
